Effects of a motor and cognitive training program on executive function and different biomarkers related to muscle-brain crosstalk in breast cancer survivors: 3-arm randomised controlled BRAINonFIT study protocol
Contemporary Clinical Trials · 2024
DOI: 10.1016/j.cct.2024.107672 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Contemporary Clinical Trials, 2024. Verfasst von Jesus Orellana-Jaén und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Seville, Pirotecnia St. E-41013 Seville, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Executive Function, Muscle Strength. Die Arbeit nennt 80 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Cancer-related cognitive impairment (CRCI) is a significant but often neglected issue for breast cancer survivors that reduces their quality of life. Physical exercise and cognitive training have emerged as promising strategies for CRCI; however, evidence regarding its effectiveness is still unknown. A recently developed motor-cognitive training (dual-tasks) is proposed to examine its efficacy on executive function, physical fitness, emotional symptomatology, and important muscle-brain crosstalk biomarkers. METHODS: The BRAINonFIT study is a randomised, controlled, longitudinal (20 weeks), three-arm, parallel study with a follow-up phase (12 weeks). Breast cancer survivors (stage I-IIIA) with completed chemotherapy are recruited from QuirónSalud Hospital in Seville. Principal outcomes are executive functions, measured by the Trail Making Test, Stroop and Digit Span Backwards; physical fitness, assessed by muscle strength, cardiorespiratory fitness, and body composition; and several muscle-brain biomarkers analysed by immunoenzymatic assay (ELISA). Secondary endpoints are memory function, intelligence, learning ability, self-reported cognitive function, and emotional symptomatology. Assessments take place after the enrolment (baseline; T1), after completing the interventions (5 months after baseline; T2), and after completing the follow-up period (8 months after baseline; T3). DISCUSSION: Given the importance of improving care for breast cancer survivors, this study will provide preliminary evidence for the effectiveness of cognitive-motor training (dual task) as a therapeutic strategy to improve CRCI. Moreover, addressing muscle-brain crosstalk by representative biomarkers will help to elucidate the underlying mechanisms by which this intervention may beneficially impact CRCI. CLINICALTRIALS: gov: NCT06073717.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Seville, Pirotecnia St. E-41013 Seville, Spain.
- Depatment of Human Motricity and Sport Performance, University of Seville, Pirotecnia St. E-41013 Seville, Spain. Electronic address: matimora@us.es.
- Department of Physical Education and Sport, University of Seville, Pirotecnia St. E-41013 Seville, Spain.
Zitieren
APA
Orellana-Jaén, J., Mora-Fernández, M., & Carrasco-Páez, L. (2024). Effects of a motor and cognitive training program on executive function and different biomarkers related to muscle-brain crosstalk in breast cancer survivors: 3-arm randomised controlled BRAINonFIT study protocol. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107672
Vancouver
Orellana-Jaén J, Mora-Fernández M, Carrasco-Páez L. Effects of a motor and cognitive training program on executive function and different biomarkers related to muscle-brain crosstalk in breast cancer survivors: 3-arm randomised controlled BRAINonFIT study protocol. Contemporary Clinical Trials. 2024. doi:10.1016/j.cct.2024.107672
BibTeX
@article{OrellanaJan2024,
author = {Orellana-Jaén, Jesus and Mora-Fernández, Matilde and Carrasco-Páez, Luis},
title = {Effects of a motor and cognitive training program on executive function and different biomarkers related to muscle-brain crosstalk in breast cancer survivors: 3-arm randomised controlled BRAINonFIT study protocol},
journal = {Contemporary Clinical Trials},
year = {2024},
doi = {10.1016/j.cct.2024.107672}
}
EUVIMED